Demand for FDA Action Amid Shuffle
Sarah Owermohle, Zachary Brennan and David Lim | Politico
“The president’s executive order for CMS to finalize a rule eliminating rebates that drugmakers pay to pharmacy benefit managers had one big caveat — the rule cannot raise seniors’ premiums, out-of-pockets costs or federal spending.
That’s an impossible bar to clear, writes Alex Brill, an economist with Matrix Global Advisors and a fellow at the American Enterprise Institute, in a new report sponsored by the PBM lobby Pharmaceutical Care Management Association.”
